Key insights
- The author presents an investment thesis arguing that Salesforce (CRM) is undervalued despite AI hype, citing its widespread adoption and reasonable P/E ratio. The portfolio also includes Microsoft (MSFT) for AI resilience, Freeport-McMoRan (FCX) for rising copper demand, Amazon (AMZN) for AI benefits in retail and AWS, and Remedy (REMEDY) for its upcoming game release. The overall sentiment is cautiously optimistic, with a slight bullish lean due to perceived undervaluation in key tech and commodity names.
I just started investing with pennies. Read my investment thesis below and rate my starting portfolio:
CRM 40,8% I have used Salesforce for years on a daily basis and given how widely it is used among the world’s biggest firms there is a lot of stickiness and I believe it is significantly undervalued due to AI hype. Although Agentforce is not ”there yet”, P/E is on a reasonable level, especially compared to previous years, and there should be room to grow.
MSFT 23,7% Azure, M365, hardware.. should be enough resiliency against AI bubble crash
FCX 15,8% One of the world’s leading copper miners. I believe demand is going to continue rising in the future and this is one of my longer-term holds.
AMZN 14,5% Not only AWS but major AI efficiency benefits in the more traditional retail side.
REMEDY 5,2% Small-cap pearl. Game studio behind Control, and co-developer of Max Payne series, Alan Wake 2. Control Resonant is going to be released soon and it has enjoyed some good early reviews and anticipation. Last time stock price increased significantly after game was released before dropping again.